Sanara MedTech shareholders approve MiMedx merger agreement at special meeting
Sanara MedTech shareholders approved the merger agreement with MiMedx Group at a special meeting on September 30, 2026, with 6,372,989 votes for and 1,944 against. Shareholders also approved, on an advisory basis, merger-related compensation for Sanara's named executive officers. The merger still depends on the expiration of the HSR Act waiting period and the satisfaction or waiver of other closing conditions.
Key points
- Proposal No. 1 (merger agreement): 6,372,989 for, 1,944 against, 36,494 abstentions
- Proposal No. 2 (advisory merger-related executive compensation): 5,841,470 for, 75,247 against, 494,710 abstentions
- HSR Act waiting period refiled September 15, 2026; expires 11:59 p.m. Eastern Time on October 15, 2026
- Quorum of 6,411,427 shares, or about 69.78% of 9,188,035 outstanding shares as of the September 1, 2026 record date
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.